Which has higher valuation and earnings, BVS or RXST?

Bioventus has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 1.26 $22.73M $0.41 20.91 RxSight $127.48M 1.56 -$38.94M -$1.13 N/A

Is BVS or RXST more profitable?

Bioventus has a net margin of 4.94% compared to RxSight's net margin of -36.58%. Bioventus' return on equity of 29.97% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 4.94% 29.97% 9.52% RxSight -36.58% -17.01% -15.12%

Which has higher earnings and valuation, RXST or CBLL?

RxSight has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RxSight $127.48M 1.56 -$38.94M -$1.13 N/A CeriBell $89.06M 7.84 -$53.41M -$1.63 N/A

Is RXST or CBLL more profitable?

RxSight has a net margin of -36.58% compared to CeriBell's net margin of -63.51%. RxSight's return on equity of -17.01% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.58% -17.01% -15.12% CeriBell -63.51% -38.19% -30.92%

Which has stronger valuation & earnings, SIBN or RXST?

SiBone has higher revenue and earnings than RxSight. SiBone is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 3.40 -$18.90M -$0.39 N/A RxSight $127.48M 1.56 -$38.94M -$1.13 N/A

Is SIBN or RXST more profitable?

SiBone has a net margin of -8.10% compared to RxSight's net margin of -36.58%. SiBone's return on equity of -9.56% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% RxSight -36.58% -17.01% -15.12%

Which has stronger earnings and valuation, RXST or BBNX?

RxSight has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RxSight $127.48M 1.56 -$38.94M -$1.13 N/A Beta Bionics $100.25M 6.45 -$73.20M -$1.51 N/A

Is RXST or BBNX more profitable?

RxSight has a net margin of -36.58% compared to Beta Bionics' net margin of -60.27%. RxSight's return on equity of -17.01% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.58% -17.01% -15.12% Beta Bionics -60.27% -23.00% -20.55%

RxSight (RXST) Competitors

$4.80 +0.10 (+2.02%)

As of 12:05 PM Eastern

Compare

RXST vs. BVS, SSII, CBLL, SIBN, and BBNX

Should you buy RxSight stock or one of its competitors? MarketBeat compares RxSight with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with RxSight include Bioventus (BVS), SS Innovations International (SSII), CeriBell (CBLL), SiBone (SIBN), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry.

How does RxSight compare to Bioventus?

Bioventus (NASDAQ:BVS) and RxSight (NASDAQ:RXST) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Bioventus has a net margin of 4.94% compared to RxSight's net margin of -36.58%. Bioventus' return on equity of 29.97% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
RxSight	-36.58%	-17.01%	-15.12%

Bioventus presently has a consensus price target of $14.00, suggesting a potential upside of 63.27%. RxSight has a consensus price target of $9.44, suggesting a potential upside of 96.55%. Given RxSight's higher possible upside, analysts plainly believe RxSight is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 33.0% of Bioventus shares are owned by company insiders. Comparatively, 10.1% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bioventus has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.26	$22.73M	$0.41	20.91
RxSight	$127.48M	1.56	-$38.94M	-$1.13	N/A

In the previous week, Bioventus had 3 more articles in the media than RxSight. MarketBeat recorded 4 mentions for Bioventus and 1 mentions for RxSight. RxSight's average media sentiment score of 1.89 beat Bioventus' score of 1.00 indicating that RxSight is being referred to more favorably in the news media.

Company	Overall Sentiment
Bioventus	Positive
RxSight	Very Positive

Bioventus has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, RxSight has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

Summary

Bioventus beats RxSight on 12 of the 17 factors compared between the two stocks.

How does RxSight compare to SS Innovations International?

RxSight (NASDAQ:RXST) and SS Innovations International (NASDAQ:SSII) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

RxSight has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, SS Innovations International has a beta of -1.89, indicating that its stock price is 289% less volatile than the broader market.

SS Innovations International has a net margin of -20.69% compared to RxSight's net margin of -36.58%. RxSight's return on equity of -17.01% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
SS Innovations International	-20.69%	-23.00%	-13.18%

SS Innovations International has lower revenue, but higher earnings than RxSight. SS Innovations International is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$127.48M	1.56	-$38.94M	-$1.13	N/A
SS Innovations International	$42.49M	16.42	-$12.13M	-$0.05	N/A

In the previous week, SS Innovations International had 1 more articles in the media than RxSight. MarketBeat recorded 2 mentions for SS Innovations International and 1 mentions for RxSight. RxSight's average media sentiment score of 1.89 beat SS Innovations International's score of 1.16 indicating that RxSight is being referred to more favorably in the media.

Company	Overall Sentiment
RxSight	Very Positive
SS Innovations International	Positive

78.8% of RxSight shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

RxSight currently has a consensus price target of $9.44, suggesting a potential upside of 96.55%. SS Innovations International has a consensus price target of $7.00, suggesting a potential upside of 100.75%. Given SS Innovations International's higher probable upside, analysts plainly believe SS Innovations International is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

RxSight beats SS Innovations International on 9 of the 16 factors compared between the two stocks.

How does RxSight compare to CeriBell?

RxSight (NASDAQ:RXST) and CeriBell (NASDAQ:CBLL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

78.8% of RxSight shares are owned by institutional investors. 10.1% of RxSight shares are owned by insiders. Comparatively, 20.1% of CeriBell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, CeriBell had 4 more articles in the media than RxSight. MarketBeat recorded 5 mentions for CeriBell and 1 mentions for RxSight. RxSight's average media sentiment score of 1.89 beat CeriBell's score of 0.56 indicating that RxSight is being referred to more favorably in the media.

Company	Overall Sentiment
RxSight	Very Positive
CeriBell	Positive

RxSight presently has a consensus price target of $9.44, indicating a potential upside of 96.55%. CeriBell has a consensus price target of $22.20, indicating a potential upside of 20.62%. Given RxSight's higher probable upside, equities research analysts plainly believe RxSight is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

RxSight has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$127.48M	1.56	-$38.94M	-$1.13	N/A
CeriBell	$89.06M	7.84	-$53.41M	-$1.63	N/A

RxSight has a net margin of -36.58% compared to CeriBell's net margin of -63.51%. RxSight's return on equity of -17.01% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
CeriBell	-63.51%	-38.19%	-30.92%

RxSight has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Summary

RxSight beats CeriBell on 11 of the 17 factors compared between the two stocks.

How does RxSight compare to SiBone?

SiBone (NASDAQ:SIBN) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, SiBone had 2 more articles in the media than RxSight. MarketBeat recorded 3 mentions for SiBone and 1 mentions for RxSight. RxSight's average media sentiment score of 1.89 beat SiBone's score of 0.60 indicating that RxSight is being referred to more favorably in the news media.

Company	Overall Sentiment
SiBone	Positive
RxSight	Very Positive

SiBone presently has a consensus target price of $23.00, indicating a potential upside of 49.16%. RxSight has a consensus target price of $9.44, indicating a potential upside of 96.55%. Given RxSight's higher possible upside, analysts plainly believe RxSight is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

98.1% of SiBone shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 3.9% of SiBone shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

SiBone has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, RxSight has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

SiBone has a net margin of -8.10% compared to RxSight's net margin of -36.58%. SiBone's return on equity of -9.56% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
RxSight	-36.58%	-17.01%	-15.12%

SiBone has higher revenue and earnings than RxSight. SiBone is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.40	-$18.90M	-$0.39	N/A
RxSight	$127.48M	1.56	-$38.94M	-$1.13	N/A

Summary

SiBone beats RxSight on 11 of the 16 factors compared between the two stocks.

How does RxSight compare to Beta Bionics?

RxSight (NASDAQ:RXST) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

RxSight currently has a consensus price target of $9.44, indicating a potential upside of 96.55%. Beta Bionics has a consensus price target of $19.70, indicating a potential upside of 35.81%. Given RxSight's higher probable upside, equities research analysts clearly believe RxSight is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

78.8% of RxSight shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Comparatively, 5.3% of Beta Bionics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

RxSight has a net margin of -36.58% compared to Beta Bionics' net margin of -60.27%. RxSight's return on equity of -17.01% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
Beta Bionics	-60.27%	-23.00%	-20.55%

RxSight has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.4, meaning that its stock price is 240% more volatile than the broader market.

In the previous week, Beta Bionics had 8 more articles in the media than RxSight. MarketBeat recorded 9 mentions for Beta Bionics and 1 mentions for RxSight. RxSight's average media sentiment score of 1.89 beat Beta Bionics' score of 0.22 indicating that RxSight is being referred to more favorably in the media.

Company	Overall Sentiment
RxSight	Very Positive
Beta Bionics	Neutral

RxSight has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$127.48M	1.56	-$38.94M	-$1.13	N/A
Beta Bionics	$100.25M	6.45	-$73.20M	-$1.51	N/A

Summary

RxSight beats Beta Bionics on 11 of the 17 factors compared between the two stocks.

Get RxSight News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXST vs. The Competition

Export

Metric	RxSight	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$199.66M	$7.10B	$6.50B	$12.37B
Dividend Yield	N/A	1.21%	2.67%	5.66%
P/E Ratio	-4.27	48.47	24.01	24.71
Price / Sales	1.56	85.51	540.55	165.59
Price / Cash	N/A	25.59	27.48	37.92
Price / Book	0.72	6.94	10.55	6.85
Net Income	-$38.94M	$159.20M	$3.56B	$337.45M
7 Day Performance	-2.93%	-0.07%	1.54%	2.70%
1 Month Performance	-15.40%	6.02%	2.48%	4.60%
1 Year Performance	-66.19%	3.02%	26.49%	32.81%

RxSight Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXST RxSight	3.435 of 5 stars	$4.81 +2.0%	$9.44 +96.6%	-66.9%	$199.66M	$127.48M	N/A	220	Positive News
BVS Bioventus	4.4725 of 5 stars	$9.23 +3.1%	$14.00 +51.7%	N/A	$770.24M	$568.09M	22.49	1,200
SSII SS Innovations International	2.9511 of 5 stars	$3.75 +6.2%	$7.00 +86.7%	-5.1%	$750.49M	$42.49M	N/A	4	Positive News Gap Up
CBLL CeriBell	2.629 of 5 stars	$18.55 +2.3%	$22.20 +19.7%	+6.9%	$704.17M	$89.06M	N/A	N/A
SIBN SiBone	2.3352 of 5 stars	$15.30 +2.2%	$23.00 +50.3%	-11.5%	$677.67M	$200.93M	N/A	350

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXST) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RxSight (RXST) Competitors